Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Schizophrenia
Interventions: lamotrigine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 21
States / cities: Little Rock, Arkansas • Garden Grove, California • Glendale, California + 17 more

Conditions: Eating Disorders
Interventions: Olanzapine, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 16 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: Placebo, bitopertin [RO4917838]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 25
States / cities: Carson, California • Garden Grove, California • Long Beach, California + 19 more

Conditions: Schizophrenia
Interventions: LB-102; Drug
Lead sponsor: LB Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 25
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 20 more

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
Interventions: olanzapine, risperidone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 31
States / cities: Little Rock, Arkansas • Escondido, California • Garden Grove, California + 28 more

Conditions: Schizophrenia
Interventions: BF2.649, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Adolescent Depression
Interventions: Bone Density Test; Radiation
Lead sponsor: Creighton University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Schizophrenia
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 446 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 15
States / cities: Costa Mesa, California • Long Beach, California • Paramount, California + 12 more

Conditions: Schizophrenia
Interventions: Pimavanserin; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 995 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 32
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Obsessive-Compulsive Disorder
Interventions: olanzapine + fluoxetine, placebo + fluoxetine; Drug
Lead sponsor: University of Florida; Other
Eligibility: 14 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2003
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Risperidone-induced Hyperprolactinemia
Interventions: Calcium and Vitamin D, Placebo; Drug · Other
Lead sponsor: Chadi A. Calarge; Other
Eligibility: 5 Years to 17 Years · Male only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Schizophrenia, Schizoaffective Disorder, Depressive Disorder, Major, Bipolar Disorder
Interventions: olanzapine versus risperidone; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2007
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Schizophrenia
Interventions: Folic Acid, Placebo; Dietary Supplement · Other
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 90 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorder, Not Otherwise Specified, Prodromal Schizophrenia, Mood Disorder, Bipolar Disorder, Major Depressive Disorder, Depressive Disorder, Not Otherwise Specified, Mood Disorder, Not Otherwise Specified, Autism Spectrum Disorder
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years to 19 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bipolar Affective Disorder
Interventions: Mood stabilizer treatment; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 8
States / cities: San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
Interventions: risperidone; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 50 Years to 95 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2011
U.S. locations: 7
States / cities: Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more

Conditions: Agitated Delirium, Delirium Confusional State, Delirium in the Intensive Care Unit, Hyperactive Delirium
Interventions: Phenobarbital, Conventional therapy group; Drug
Lead sponsor: Duke University; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Schizophrenia
Interventions: LY2140023, aripiprazole, olanzapine, risperidone; Drug
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more

Conditions: Schizophrenia With Impulsivity
Interventions: Brexpiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Orange, California

Conditions: Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions: Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 6
States / cities: Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more

Conditions: Schizophrenia
Interventions: paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 55
States / cities: Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more

Conditions: Child Mental Disorders, Obesity, Metabolic Syndrome
Interventions: Behavioral Weight Loss, Diet and Exercise Education; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 18 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder (MDD)
Interventions: GeneSight Psychotropic; Genetic
Lead sponsor: Assurex Health Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 61
States / cities: Birmingham, Alabama • Bellflower, California • Chino, California + 52 more

Conditions: Schizophrenia
Interventions: Olanzapine, Perphenazine, Aripiprazole, Metformin, Simvastatin, Benztropine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 13
States / cities: Colton, California • Palo Alto, California • New Haven, Connecticut + 10 more

Search by objective public record fields.

Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia

Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy

Safety and Efficacy of Cariprazine in Schizophrenia

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Treatment of Obsessive-Compulsive Disorder

Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia

Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder

Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects

Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study

Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)

Antipsychotic Discontinuation in Alzheimer's Disease

Phenobarbital for Agitated Delirium

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated

Healthy Bodies, Healthy Kids

Genomics Used to Improve DEpression Decisions

Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia